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An assessment of the concentrations of thirteen different therapeutic pharmaceutical compounds was conducted
on water samples obtained from different wastewater treatment plants (WWTPs) using solid phase extraction and
high- and ultra-high-performance liquid chromatography with mass spectrometry detection (HPLC-MS/MS and
UHPLC-MS/MS), was carried out.
The target compounds included ketoprofen and naproxen (anti-inflammatories), bezafibrate (lipid-regulating),
carbamazepine (anticonvulsant), metamizole (analgesic), atenolol (β-blocker), paraxanthine (stimulant), fluoxetine
(antidepressant), and levofloxacin, norfloxacin, ciprofloxacin, enrofloxacin and sarafloxacin (fluoroquinolone
antibiotics).
The relative standard deviations obtained in method were below 11%, while the detection and quantification limits
were in the range of 0.3 – 97.4 ng·L-1 and 1.1 – 324.7 ng·L-1, respectively. The water samples were collected from
two different WWTPs located on the island of Gran Canaria in Spain over a period of one year. The first WWTP
(denoted as WWTP1) used conventional activated sludge for the treatment of wastewater, while the other plant
(WWTP2) employed a membrane bioreactor system for wastewater treatment.
Most of the pharmaceutical compounds detected in this study during the sampling periods were found to have
concentrations ranging between 0.02 and 34.81 μg·L-1.
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WastewaterIntroduction
Many modern pollution problems are a result of the inter-
mittent or continuous release of chemical substances into
the environment. Their presence is one of the main emer-
ging issues that the organisations committed to public and
environmental health have to address (Hernando et al.
2006a). Pharmaceutical compounds within this group of
pollutants have raised increasing concerns over the last two
decades because their effects on the environment are un-
known. Thousands of tons of pharmaceuticals are used
every year, in both human and veterinary medicine, and are* Correspondence: jsantana@dqui.ulpgc.es
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reproduction in any medium, provided the origreleased to the environment through metabolic excretion
and improper disposal techniques. These compounds are
not completely degraded at the wastewater treatment plants,
and many of them are discharged into the environment
through many sources and pathways (Wick et al. 2009).
These pharmaceutical compounds are objects of evalu-
ation for their potential effects on aquatic organisms
(Sanderson et al. 2004) and non-target species (Fent
et al. 2006). The monitoring of these pharmaceuticals is
therefore required to provide a greater knowledge with
respect to their occurrence, their distribution in the en-
vironment and what effects they have on organisms
when these organisms are exposed to low levels of
pharmaceutical compounds (Pal et al. 2010).is is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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matrices such as blood, plasma or urine has been developed
over a long period of time (Erny and Cifuentes 2006).
Nevertheless, there is a greater difficulty in quantifying
pharmaceuticals found in complex environmental samples
because the concentrations of these compounds are very
low and there are many compounds that can be quantified.
Gas chromatography (GC) and liquid chromatography
(LC) are the most common techniques used to monitor the
concentrations of organic contaminants in the environment
(Hernando et al. 2006b; Zhang et al. 2011; Busetti et al. 2006;
Gómez et al. 2007). Polar, non-volatile or thermally degrad-
able compounds and their derivatives cannot be analysed by
GC, and LC is an essential tool for the analysis of these types
of compounds (Chen et al. 2008; Castiglioni et al. 2005).
Liquid chromatography with tandem-mass spectrometry
(LC-MS/MS) is the most commonly used technique (Wu
et al. 2008; Baranowska and Kowalski 2010; Gros et al. 2012).
The low concentrations of pharmaceutical compounds in
environmental samples render the employment of pre-
treatment procedures such as the preconcentration and purifi-
cation of these compounds to be necessary. The most
common technique used to extract and preconcentrate
pharmaceutical compounds present in environmental
water samples is solid-phase extraction (SPE) (Pavlović
et al. 2010; Afonso-Olivares et al. 2012; Montesdeoca-
Esponda et al. 2012).
In this work, we present a monitoring of three groups of
pharmaceutical compounds in wastewater samples. Group 1
consists of ketoprofen, naproxen, bezafibrate and carba-
mazepine, Group 2 consists of metamizole, atenolol,
paraxanthine and fluoxetine and a third group consists of
five fluoroquinolones, namely levofloxacin, norfloxacin,
ciprofloxacin, enrofloxacin and sarafloxacin. Table 1 shows
the structures and characteristics of the selected compounds.
To do the monitoring, we have used the SPE, the LC-MS/
MS and the UHPLC-MS/MS procedures that have previ-
ously been optimised by our group (Afonso-Olivares et al.
2012; Montesdeoca-Esponda et al. 2012). The selection of
these pharmaceutical compounds was mainly based on the
consumption of these compounds by the population.
The water effluent samples were collected bimonthly
between January 2011 and December 2011 from two dif-
ferent wastewater treatment plants (WWTPs) located on
Gran Canaria Island in Spain. The first WWTP (denoted
as WWTP1) used conventional activated sludge method
for the treatment of wastewater, while the other plant




All the pharmaceutical compounds and fluoroquinolones
used were purchased from Sigma–Aldrich (Madrid,Spain). Stock solutions containing 1000 mg·L-1 of each
analyte were prepared by dissolving the compound in
methanol, and the solutions were stored in glass-
stoppered bottles at 4°C prior to use. Working aqueous
standard solutions were prepared daily. Ultrapure water
was provided by a Milli-Q system (Millipore, Bedford,
MA, USA). HPLC-grade methanol, LC-MS methanol, and
LC-MS water as well as the formic acid and the ammo-
nium formate used to adjust the pH of the LC-MS and
UHPLC-MS mobile phases were obtained from Panreac
Química (Barcelona, Spain). Polyoxyethylene 10 lauryl
ether (POLE) was obtained from Sigma-Aldrich (Madrid,
Spain) and prepared in Milli-Q water.
Sample collection
Water samples were collected bimonthly from the efflu-
ent of two wastewater treatment plants located in the
northern part of Gran Canaria in 2011. WWTP1 utilised
a conventional activated sludge treatment system, while
WWTP2 employed a membrane bioreactor treatment
system. The samples were collected in 2 L amber glass
bottles that were rinsed beforehand with methanol and
water. Samples were purified through filtration with
fibreglass filters and 0.65 μm membrane filters (Millipore,
Ireland). The samples were stored in the dark at 4°C and
extracted within 48 hours. Influent samples were not
analysed, so the degradation of the compounds during
treatment was not evaluated.
Instrumentation
The analysis of all pharmaceutical compounds except
fluoroquinolones was performed in a Varian system
(Varian Inc., Madrid, Spain), which consisted of a 320-
MS LC/MS/MS system (triple quadrupole) equipped
with an electrospray ionisation (ESI) interface, two
pumps and a column valve module with an internal oven
and an autosampler. The software used to control the
system was MS Varian LC/MS Workstation Version 6.9.
The housing and desolvation temperatures were set at
60 and 250°C, respectively, for optimisation. Nitrogen
was used as a nebuliser and a drying gas. Nebulisation
was conducted at a pressure of 30 psi, and drying was
conducted at a pressure of 65 psi. The capillary voltage
was set to 4.5 kV in the positive mode (ESI+) and −3 kV
in the negative mode (ESI–). The shield was pro-
grammed at −600/600 V (ESI+/ESI–), and the cone volt-
age was optimised for each compound. Collision-
induced dissociation (CID) was conducted with argon as
the collision gas at 1.94 psi.
The analysis of fluoroquinolones was performed in a
UHPLC system from Waters (Madrid, Spain) consisting
of an ACQUITY Quaternary Solvent Manager (QSM)
used to load samples and wash and recondition the ex-
traction column, an ACQUITY Binary Solvent Manager
Table 1 List of pharmaceutical compounds, identification number, pKa values, chemical structure and retention times
Group of compounds Identification number Compound pKa Structure tR (min)
1 1 Naproxen 5.24 4.30
2 Carbamazepine 13.9 2.14
3 Ketoprofen 4.45 3.24
4 Bezafibrate - 5.52
2 5 Atenolol 9.64 7,23
6 Metamizole - 8,26
7 Paraxanthine 8.5 11,23
8 Fluoxetine 8.8 17,97
3 9 Levofloxacin - 2,03
10 Norfloxacin 6.4 2,23
11 Ciprofloxacin 5.9 2,61
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12 Enrofloxacin - 3,16
13 Sarafloxacin - 4,76
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2777 autosampler equipped with a 25 μL syringe and a tray
to hold 2 mL vials, and a ACQUITY tandem triple quadru-
pole (TQD) mass spectrometer with an electrospray
ionization (ESI) interface. All Waters components (Madrid,
Spain) were controlled using the MassLynx Mass Spectrom-
etry Software. The electrospray ionisation parameters were
fixed as follows: the capillary voltage was 3 kV, the cone volt-
age was 50 V, the source temperature was 120°C, the
desolvation temperature was 450°C, and the desolvation gas
flow rate was 800 L/hr. Nitrogen was used as the desolvation
gas, and argon was employed as the collision gas.
The detailed MS/MS detection parameters for each
pharmaceutical compound are presented in Table 2 and
were optimised by the direct injection of a 1 mg·L-1
standard solution of each analyte into the detector at a
flow rate of 10 μL·min-1.Table 2 Mass spectrometer parameters for the determination
Nº Compound Precursor ion (m/z) Capillary vo
(Ion mo
1 Naproxen 231.2 36 (ESI
2 Carbamazepine 237.1 40 (ESI
3 Ketoprofen 255.1 52 (ESI
4 Bezafibrate 359.8 64 (ESI
5 Atenolol 267.0 52 (ESI
6 Metamizole 218.0 30 (ESI
7 Paraxanthine 181.0 40 (ESI
8 Fluoxetine 310.0 30 (ESI
9 Levofloxacin 362.3 40 (ESI
10 Norfloxacin 320.3 40 (ESI
11 Ciprofloxacin 332.3 40 (ESI
12 Enrofloxacin 360.3 40 (ESI
13 Sarafloxacin 386.3 40 (ESIChromatographic conditions
For Group 1 (ketoprofen, naproxen, bezafibrate and carba-
mazepine), the chromatographic column used was a
2.0 mm × 50 mm, Pursuit UPS C18 column with a particle
size of 2.4 μm. The mobile phase used was a mixture of
water containing 0,2% formic acid and 5 mM ammonium
formate at a pH of 2.6 and methanol. A gradient
programme started the elution at a 50:50 v/v mixture of
water–methanol, which changed to 40:60 (v/v) for 9 minutes,
following which it returned to the initial ratio in the next
minute and stayed calibrating for another minute. The flow
rate was 0.2 mL·min-1, and the injection volume of the
analyte was 10 μL.
For group 2 (metamizole, atenolol, paraxanthine and
fluoxetine), the chromatographic column was a 3.0 mm ×
100 mm, SunfireTM C18 column with a particle size of







+) 153.1 (28.5) 170.0 (22.0)
+) 194.0 (13.5) 192.0 (17.0)
+) 209.0 (10.0) 104.9 (18.5)
-) 273.7 (15.5) 153.5 (28.5)
+) 145.0 (23.5) 190.0 (16.5)
+) 56.0 (12.5) 97.0 (11.5)
+) 124.0 (17.0)
+) 44.0 (6.5) 148.0 (5.5)
+) 318.3 (20.0) 261.2 (30.0)
+) 302.3 (20.0) 276.2 (15.0)
+) 314.3 (22.0) 288.2 (18.0)
+) 316.3 (20.0) 245.3 (25.0)
+) 368.3 (20.0) 299.2 (30.0)
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analysis of group 1 compounds. The water:methanol gra-
dient was started at 90:10 v/v. It changed to 45:55 v/v for
13 minutes and then to 35:65 in the next minute. Finally,
the gradient was changed to 90:10 v/v after 16 minutes
and stayed calibrating for another 5 minutes.
For the third group (levofloxacin, norfloxacin,
ciprofloxacin, enrofloxacin and sarafloxacin), the analyt-
ical column was a 50 mm × 2.1 mm, ACQUITY UHPLC
BEH Waters C18 column with a particle size of 1.7 μm
(Waters Chromatography, Barcelona, Spain) operating at
a temperature of 40°C. The mobile phases were water,
adjusted to a pH of 2.5 with 0.1% v/v formic acid, and
methanol. The analysis was performed in isocratic mode,
using a 50:50 v/v water–methanol mixture at a flow rate
of 0.3 mL·min-1. The sample volume injected was 10 μL.
Solid-phase extraction
SPE conditions were optimised in previous studies
(Afonso-Olivares et al. 2012; Montesdeoca-Esponda et al.
2012). Cartridges were conditioned with 5 ± 0.05 mL of
methanol and 5 ± 0.05 mL of Milli-Q water at a flow-rate
of 5 mL · min-1 before each run. The sample was then
passed through the cartridge at a flow of 10 mL · min-1. A
wash step was conducted using 5 ± 0.05 mL of Milli-Q
water to remove any impurities. The cartridges were dried
under vacuum for 10 minutes, and the analytes were
eluted at an approximate flow rate of 1 mL · min-1.
For Groups 1 and 2, the SPE cartridge used was an
OASIS HLB 6 mL/200 mg cartridge (Waters, Spain). The
sample volume was 250 ± 0.15 mL at a pH of 8.00 ± 0.01
and contained 0% w/v of sodium chloride. The desorption
volume was 2 ± 0.02 mL of methanol. The eluents were
then evaporated under a gentle nitrogen stream and
reconstituted with 1 ± 0.01 mL of LC-MS grade water.
These operating conditions for SPE allowed the samples
to be preconcentrated by a factor of 250.
For Group 3, the SPE cartridge used was an OASIS
HLB 6 mL/200 mg cartridge (Waters, Spain). The sample
volume was 200 ± 0.15 mL at a pH of 3.00 ± 0.01 and
contained 0% w/v of sodium chloride, and the desorption
volume was 1 ± 0.01 mL of polyoxyethylene 10 lauryl
ether (POLE) (Montesdeoca-Esponda et al. 2012). These
operating conditions for SPE allowed the fluoroquinolones
to be preconcentrated by a factor of 200.
Results and discussion
Analytical parameters
An external calibration was used for the quantification
of the analytes by diluting the stock solution to six
concentrations ranging between 1 and 500 μg·L-1,
where each point corresponds to the mean value
obtained from three area measurements. Analysis was
conducted by LC-MS/MS for Group 1 and Group 2compounds, and UHPLC-MS/MS was used for the
fluoroquinolone group. Linear calibration plots for each
analyte (r2 > 0.99) were obtained based on their chro-
matographic peak areas.
The limit of detection (LOD) and the limit of quantifi-
cation (LOQ) for each compound were calculated from
the signal to noise ratio of each individual peak in
wastewater samples spiked with the analytes. The LOD
was defined as the lowest concentration that gave a sig-
nal to noise ratio that was equal to 3. The LOQ was
defined to be the lowest concentration that gave a signal
to noise ratio that was equal to 10. The LODs ranged
from 0.3 – 7.9 ng · L-1 for Groups 1 and 2 and 5.3 –
11.1 ng · L-1 for the fluoroquinolones. The LOQs for
Group 1 and Group 2 ranged from 1.1 – 26.3 ng · L-1,
and they ranged from 17.7 to 37.0 ng · L-1 for the
fluoroquinolones. Only Fluoxetine presented LOD and
LOQ higher (97.4 and 324.7 respectively) because the
transitions of fluoxetine presents more noise, so, the re-
lation between signal and noise is lower, increasing the
detection and quantification limits.
The performance and reliability of the process was
studied by determining the repeatability of the quantifi-
cation results for all target analytes under the described
conditions. Six replicate samples were employed,
obtaining relative standard deviations (RSDs) lower than
11% in all cases, indicating a good repeatability. Finally,
the recoveries of the SPE methods were measured in 6
real samples and they were over 67%, except for
metamizole and fluoxetine (54 and 21% respectively).
Table 3 shows the analytical parameters obtained for all
compounds analysed.
Analysis of selected compounds in wastewater samples
The SPE extraction procedure was combined with the LC-
MS/MS and the UHPLC-MS/MS detection methods for
monitoring wastewater effluents from two different WWTPs
located on Gran Canaria Island in Spain. The samples were
collected once every two months over the duration of a year.
The first plant (WWTP1) uses the conventional activated
sludge method for the treatment of wastewater, while the sec-
ond plant (WWTP2) employs a membrane bioreactor (MBR)
system for wastewater treatment. Both WWTPs operate at
similar daily influent sewage volumetric flow rates (500 m3/
day for WWTP1 and 700 m3/day for WWTP2) and treat the
wastewater from similarly sized populations (5,000 inhabitants
for WWTP1 and 7,000 inhabitants for WWTP2). Figure 1,
demonstrate the MRM chromatograms corresponding to
wastewater samples from WWTP1 that contain compounds
from Groups 1 and 2 respectively. The results of the
measurements are shown in Table 4.
We can observe that the concentrations of the group 1
compounds range consistently from 0.05 and 0.30
μg·L-1 for naproxen, carbamazepine and ketoprofen.
Table 3 Analytical parameters for the SPE-LC-MS/MS and SPE-UHPLC-MS/MS methods
Nº Compound RSDa (%) n=6 LODb (ng/L) LOQc (ng/L) Recovery (%) n=6
1 Naproxen 9.6 0.6 1.8 101.8 ± 7.0
2 Carbamazepine 10.7 0.3 1.1 105.6 ± 4.4
3 Ketoprofen 9.2 2.4 7.9 98.6 ± 9.4
4 Bezafibrate 7.8 2.9 9.6 91.6 ± 11.4
5 Atenolol 6.5 7.9 26.3 67.2 ± 4.4
6 Metamizole 7.9 6.3 21.1 54.4 ± 4.3
7 Paraxanthine 10.8 2.2 7.8 96.4 ± 10.4
8 Fluoxetine 7.7 97.4 324.7 21.0 ± 1.6
9 Levofloxacin 8.5 9.1 30.3 82.4 ± 14.0
10 Norfloxacin 8.5 8.5 28.0 85.3 ± 5.2
11 Ciprofloxacin 6.8 8.6 28.7 86.2 ± 2.1
12 Enrofloxacin 7.0 5.3 17.7 94.0 ± 6.1
13 Sarafloxacin 9.8 11.1 37.0 86.1 ± 11.2
aRelative Standard Derivation.
bDetection limits, calculated as signal to noise ratio of three times.
cQuantification limits, calculated as signal to noise ratio of ten times.
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and 2.15 μg·L-1. WWTP1 has higher naproxen,
ketoprofen and bezafibrate concentrations that WWTP2
and a similar effluent concentration for carbamazepine.
There are more notable differences in the analysis of
the pharmaceuticals in Group 2. In WWTP1, atenolol
concentrations range between 0.04 and 0.95 μg·L-1, ex-
cept in one sample (July 2011), where the concentrationFigure 1 Chromatogram of WWTP1 sample with LC/MS-MS detectionwas 2.95 μg·L-1. Metamizole concentrations range be-
tween 0.25 and 3.45 μg·L-1, while the concentrations of
paraxanthine are higher, ranging between 8.36 and
34.81 μg·L-1. The higher detected concentrations of
paraxanthine can be explained through the fact that this
compound is a metabolite of caffeine in the human
body. In WWTP2, the concentrations of atenolol and
metamizole are lower, except for metamizole in the Mayfor Groups 1 and 2 of compounds.
Table 4 Concentrations in μg·L-1 found in treated water samples from two wastewater treatment plants of Gran
Canaria islanda
WWTP Date Naproxen Carbamazepine Ketoprofen Bezafibrate
WWTP1 Jan-2011 0.06 ± 0.01 0.51 ± 0.01 0.78 ± 0.08 2,15 ± 0.37
Mar-2011 0.10 ± 0.03 0.06 ± 0.01 0.22 ± 0.06 0.51 ± 0.05
May-2011 0.08 ± 0.01 0.02 ± 0.00 0.26 ± 0.03 1.50 ± 0.02
July-2011 0.25 ± 0.00 0.19 ± 0.01 1.36 ± 0.03 ndb
Sept-2011 ndb ndb 0.07 ± 0.01 0.04 ±0.01
Nov-2011 0.15 ±0.01 0.04 ± 0.00 0.14 ± 0.00 0.37 ± 0.07
WWTP2 Jan-2011 ndb 0.97 ± 0.03 0.11 ± 0.01 ndb
Mar-2011 ndb 0.36 ± 0.03 ndb ndb
May-2011 0.05 ± 0.01 0.08 ± 0.00 0.30 ± 0.01 2.13 ± 0.08
July-2011 ndb 0.67 ± 0.06 0.06 ± 0.00 ndb
Sept-2011 ndb 0.19 ± 0.02 0.05 ± 0.01 ndb
Nov-2011 0.21 ± 0.02 0.24 ± 0.00 0.05 ± 0.00 ndb
WWTP Date Atenolol Metamizole Paraxanthine Fluoxetine
WWTP1 Jan-2011 0.31 ± 0.01 3,45 ± 2.33 12.31 ± 0.83 ndb
Mar-2011 0.61 ± 0.20 0.41 ± 0.15 8.36 ± 0.02 ndb
May-2011 0.65 ± 0.03 ndb ndb ndb
July-2011 2.95 ± 0.03 0.80 ± 0.01 ndb ndb
Sept-2011 0.95 ± 0.12 1.65 ± 0.21 34.81 ± 1.64 ndb
Nov-2011 0.04 ± 0,00 0.25 ± 0.08 nd ndb
WWTP2 Jan-2011 ndb ndb ndb ndb
Mar-2011 0.07 ± 0.01 1.19 ± 1.06 ndb ndb
May-2011 ndb 8.25 ± 0.19 ndb ndb
July-2011 0.12 ±0.01 0.24 ± 0.02 ndb ndb
Sept-2011 0.26 ± 0.04 0.62 ± 0.14 ndb ndb
Nov-2011 0.04 ± 0.00 0.25 ± 0.08 ndb ndb
WWTP Date Levofloxacin Norfloxacin Ciprofloxacin Enrofloxacin Sarafloxacin
WWTP1 Jan-2011 4.40 ± 0.20 ndb ndb ndb ndb
Mar-2011 2.93 ± 0.17 ndb 11.1 ± 0.75 ndb ndb
May-2011 3.70 ± 0.28 ndb 20.3 ±1.81 ndb ndb
July-2011 ndb ndb ndb ndb ndb
Sept-2011 ndb ndb ndb ndb ndb
Nov-2011 0.44 ± 0.03 ndb ndb ndb ndb
WWTP2 Jan-2011 5.90 ± 0,59 ndb ndb ndb ndb
Mar-2011 14.1 ± 0.92 ndb ndb ndb ndb
May-2011 6.24 ± 0.28 ndb 16.02 ± 0.82 ndb ndb
July-2011 ndb ndb ndb ndb ndb
Sept-2011 ndb ndb ndb ndb ndb
Nov-2011 ndb ndb ndb ndb ndb
an = 3.
bnd = not detected.
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all, while fluoxetine was not detected in either of the WWTPs.
The concentrations of the fluoroquinolones in both
WWTPs are similar, ranging between 2.93 and 14.1 μg·L-1
for levofloxacin and between 11.1 and 20.3 μg·L-1 for
ciprofloxacin. Norfloxacin, enrofloxacin and sarafloxacin
were not detected in either of the WWTPs.
In summary, the concentrations of the pharmaceuticals
and antibiotics detected at the wastewater treatment plant
that operated with a membrane bioreactor treatment sys-
tem are lower than that of the WWTP operating with a
traditional technique such as activated sludge. Therefore,
if the influent water quality of both the WWTPs is similar,
the membrane bioreactor technique (MBR) can be said to
be more efficient than the activated sludge technique.
Conclusions
A survey on the presence of pharmaceutical compounds
in two wastewater treatment plants on the island of Gran
Canaria in Spain was conducted. The scope of this study
included eight common pharmaceutical compounds (na-
proxen, carbamazepine, ketoprofen, bezafibrate, atenolol,
metamizole, paraxanthine and fluoxetine) and five
fluoroquinolones (levofloxacin, norfloxacin, ciprofloxacin,
enrofloxacin and sarafloxacin). Wastewater effluent
samples were collected bimonthly in 2011. During the
monitoring period, 9 analytes were detected in all samples,
with analgesics, anti-inflamatories and lipid regulators
being the most frequently detected compounds.
A group of fluoroquinolones was selected for analysis be-
cause they were considered “priority pollutants” due to their
potential hazardous effects on the aquatic environment.
The results show that the elimination of most of the
analysed compounds is incomplete, but the membrane
bioreactor technique is the more efficient of the two
wastewater treatment process analysed in the removal of
pharmaceutical compounds, and it results in lower efflu-
ent concentrations for most of the compounds in com-
parison with the activated sludge technique.
The results obtained in this monitoring work support
the motivation for including pharmaceutical compounds
in the monitoring of wastewater effluent quality.
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